ConductScience.org, home

Paper39397484

Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.

Moakes CA and 14 others. Health Technol Assess, 2024. Cited by 7 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT. Papers, record 39397484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39397484

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.
PubMed
Journal
Health Technol Assess
PubMed
Year
2024
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Clinical Trial, Phase III, Pragmatic Clinical Trial, Equivalence Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
1.64, provisional
iCite
Revised in PubMed
2026-07-17
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cost-Benefit AnalysisMajor topic
Endovascular ProceduresMajor topic
Amputation, SurgicalMajor topic
Quality-Adjusted Life YearsMajor topic
Chronic Limb-Threatening IschemiaMajor topic
Humans
Male
Female
Aged
Popliteal Artery
Peripheral Arterial Disease
Middle Aged
Quality of Life
United Kingdom
Technology Assessment, Biomedical
Limb Salvage
Ischemia

Source PubMed

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,481,898Procedural and 12-month in-hospital costs of primary infra-popliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia.J Vasc Surg2022https://conductscience.org/library/papers/34481898PubMed
235,680,042Prediction Models for Two Year Overall Survival and Amputation Free Survival After Revascularisation for Chronic Limb Threatening Ischaemia.Eur J Vasc Endovasc Surg2022https://conductscience.org/library/papers/35680042PubMed
326,739,146Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial.Trials2016https://conductscience.org/library/papers/26739146PubMed
421,479,777Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).Qual Life Res2011https://conductscience.org/library/papers/21479777PubMed
59,794,854Analysis and interpretation of cost data in randomised controlled trials: review of published studies.BMJ1998https://conductscience.org/library/papers/9794854PubMed
628,602,580A Comparison of Outcomes in Patients with Infrapopliteal Disease Randomised to Vein Bypass or Plain Balloon Angioplasty in the Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL) Trial.Eur J Vasc Endovasc Surg2017https://conductscience.org/library/papers/28602580PubMed
715,150,820Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies.Diabetes Metab Res Rev2004https://conductscience.org/library/papers/15150820PubMed
833,527,304The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data.Appl Health Econ Health Policy2021https://conductscience.org/library/papers/33527304PubMed
929,599,067
Editor's Choice - A Comparison of Clinical Outcomes Between Primary Bypass and Secondary Bypass After Failed Plain Balloon Angioplasty in the Bypass versus Angioplasty for Severe Ischaemia of the Limb (BASIL) Trial.
Eur J Vasc Endovasc Surg2018https://conductscience.org/library/papers/29599067PubMed
1028,102,550Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement.Stat Med2017https://conductscience.org/library/papers/28102550PubMed
1121,963,765
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol2011https://conductscience.org/library/papers/21963765PubMed
1216,900,281The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations.Qual Life Res2006https://conductscience.org/library/papers/16900281PubMed
137,827,647Costs, effects and C/E-ratios alongside a clinical trial.Health Econ1994https://conductscience.org/library/papers/7827647PubMed
142,115,096The CE plane: a graphic representation of cost-effectiveness.Med Decis Making1990https://conductscience.org/library/papers/2115096PubMed
1520,307,380
Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial.
Health Technol Assess2010https://conductscience.org/library/papers/20307380PubMed
1620,435,260
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification.
J Vasc Surg2010https://conductscience.org/library/papers/20435260PubMed
1731,230,866Editor's Choice - The Prognostic Value of the WIfI Classification in Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-Analysis.Eur J Vasc Endovasc Surg2019https://conductscience.org/library/papers/31230866PubMed
1837,116,524
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.
Lancet2023https://conductscience.org/library/papers/37116524PubMed
1931,303,293Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis.Lancet Glob Health2019https://conductscience.org/library/papers/31303293PubMed
2036,342,173Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia.N Engl J Med2022https://conductscience.org/library/papers/36342173PubMed

See all 53 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42,920,533
Sitting Baduanjin-based rehabilitation programme following endovascular therapy in patients with chronic limb-threatening ischemia: protocol for a WeChat mini program-assisted multicentre randomized controlled trial.
Front Cardiovasc Med2026https://conductscience.org/library/papers/42920533PubMed
42,550,504Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia.JAMA Netw Open2026https://conductscience.org/library/papers/42550504PubMed
42,196,923From Angiosome to Woundosome: An Interdisciplinary Approach to Personalized Revascularization in Chronic Limb-Threatening Ischemia.Diagnostics (Basel)2026https://conductscience.org/library/papers/42196923PubMed
40,564,084Preliminary Evaluation of 3D-Printed Alginate/Gelatin Scaffolds for Protein Fast Release as Suitable Devices for Personalized Medicine.Biomedicines2025https://conductscience.org/library/papers/40564084PubMed
40,097,243Algorithm for the Revascularization of Infrainguinal Arterial Disease.Vasc Specialist Int2025https://conductscience.org/library/papers/40097243PubMed

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
ISRCTNISRCTN27728689

Source ISRCTN

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39397484

GET https://conductscience.org/api/papers/v1/39397484/references?page=2